Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases

Trevisiol, Chiara; Fabio, Francesco Di; Nascimbeni, Riccardo; Peloso, L.; Salbe, C.; Ferruzzi, E.; Salerni, Bruno; Gion, Massimo

doi:10.5301/jbm.2008.3336

Cited by 22 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum KRAS2 status was significantly associated with Dukes' stage D and with preoperative CA 19-9 levels. At multivariate analysis, cancer-related survival was associated with Dukes' stage, CEA level, and mutant circulating KRAS2 [87]. These data are in accordance with the earlier study, which demonstrated an association between the presence of postoperative serum mutant KRAS2 and disease recurrence of CRC patients [88].…”

Section: Cirdna Mutations In Different Cancerssupporting

confidence: 90%

“…Some patients with no evidence of colon neoplasia showed a mutant K-ras DNA in plasma, but the presence of mutant K-ras DNA was significantly associated with risk factors for colorectal cancer. Serum KRAS2 status appeared to correlate with prognosis in stage D colorectal carcinoma patient subgroup, thus it may impact substantially on the management of these patients [87]. KRAS2 mutations were found in tissue samples of 28 patients (33%); serum KRAS2 mutations were detected in 10 of them (36%).…”

Section: Cirdna Mutations In Different Cancersmentioning

confidence: 97%

See 1 more Smart Citation

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Vlassov¹,

Laktionov²,

Rykova³

2010

CMM

View full text Add to dashboard Cite

Since the association of circulating DNA level changes with tumor growth was discovered many attempts have been made to develop the sensitive and robust blood-based tests for early tumor diagnostics. Both genomic as well as mitochondrial DNA quantification in the circulation have been extensively evaluated as a diagnostic and prognostic tool to monitor cancer therapy. Cell-free DNA bearing the same genetic and epigenetic changes as the tumor tissues were shown to be detectable in plasma / serum of cancer patients indicating the principal possibility to create the minimally invasive diagnostic tests based on tumor-specific DNA markers. Apart from circulating DNA, tumor-derived RNA in plasma / serum was found to be a promising approach for the development of cancer markers. Results of the last two years establish the quantification of the tumor-derived microRNAs in plasma / serum as an extremely promising approach for cancer diagnostics. The aim of this publication was to review the recently reported studies on the circulating DNA and RNA in cancer patients and to estimate their impact on making the ongoing research closer to clinical application.

show abstract

Section: Cirdna Mutations In Different Cancerssupporting

confidence: 90%

Section: Cirdna Mutations In Different Cancersmentioning

confidence: 97%

Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers

Vlassov¹,

Laktionov²,

Rykova³

2010

CMM

View full text Add to dashboard Cite

show abstract

“…In another study it was detected the amount of circulating tumor DNA in 18 MCRC patients who underwent surgical resection of their metastases and it was observed that the detection of circulating mutant DNA after surgery was highly predictive of disease recurrence [66]. These results were agree with those of a previous study in which the probability to have a curative surgical resection has been shown to be lower in MCRC patients with measurable KRAS mutation in their serum [67].…”

Section: Colorectal Cancersupporting

confidence: 84%

“…This is partly due to KRASmutation, which is currently assessed in the primary tumor. Many studies assessed mutation status in circulating tumor DNA, with the aim to improve patient selection [65], [66], [67] and [68].…”

Section: Colorectal Cancermentioning

confidence: 99%

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities

Espósito¹,

Bardelli²,

Criscitiello³

et al. 2014

Cancer Treatment Reviews

104

View full text Add to dashboard Cite

Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The "liquid biopsy" provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence. This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected.

show abstract

“…Из них только у 36 % данные изменения регистрировались в цДНК. Исследователи подтвердили негативное про-гностическое значение наличия мутации в гене KRAS цДНК у больных с метастатическим заболеванием [49]. Негативное прогностическое значение выявления му-тации в гене KRAS цДНК при метастатическом и опе-рабельном раке толстой кишки было показано и дру-гими исследовательскими группами [50,51].…”

unclassified